tbuckley/cabot-search huggingface dataset:
In the Absence of Proof
Authors: Sameer Kushwaha, Isaac I. Bogoch, Susanna Mak, Patrik Rogalla, Allan S. Detsky
Journal: New England Journal of Medicine (2020)

A previously healthy 50-year-old man presented to the emergency department with a 5-day history of sharp pleuritic chest pain on the left side, dry cough, and palpitations and a 4-week history of intermittent fevers, chills, anorexia, weight loss, and fatigue.
Efficacy and Safety of Ruxolitinib and Steroids for Treating Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
Authors: James R. Berenson, Noemi Silagan, Jennifer To, Tanya M. Spektor, Daisy Martinez, Armando J. Sanchez, Eli Forouzan, Regina Swift, Benjamin Eades, Gary Schwartz, Shahrooz Eshaghian, Ralph V. Boccia, Honghao Hank Yang, Stephen Lim, Robert Vescio
Journal: Blood (2020)
Polatuzumab Vedotin in Relapsed and Refractory (r/r) Large B-Cell Lymphoma (LBCL): Real-World Data of the German National Compassionate Use Program (CUP)
Authors: Nora Liebers, Johannes Duell, Daniel Nörenberg, Eva Kaebisch, Andrea Kerkhoff, Fabian Acker, Stephan Fuhrmann, Corinna Leng, Manfred Welslau, Jens Chemnitz, Jan Moritz Middeke, Thomas Weber, Ralf Ulrich Trappe, Roald Pfannes, Ruediger Liersch, Christian Spoer, Niklas Gebauer, Stefan Fuxius, Léandra Caillé, Christiane Pott, Christian Koenecke, Udo Holtick, Thomas Geer, Ulrich Keller, Rainer Claus, Dimitrios Mougiakakos, Stephanie Mayer, Andreas Hüttmann, Arne Trummer, Gerald Wulf, Uta Brunnberg, Lars Bullinger, Georg Hess, Carsten Mueller-Tidow, Bertram Glass, Georg Lenz, Peter Dreger, Sascha Dietrich
Journal: Blood (2020)
転移性結腸直腸癌(MCRC)患者の第一線治療としてのFOLFIRINOXと併用したセツキシマブを評価する多施設第二相試験の最終結果
Authors: Samalin E, Desseigne F, Thezenas S, Bibeau F, Viret F, Mineur L, Assenat E, Bleuse J, Portales F, Crapez E, Ychou M
Journal: Annals of Oncology (2009)
The power of caring in clinical encounters
Authors: Paul Dieppe, Ian Fussell, Sara L Warber
Journal: BMJ (2020)

### What you need to know "One of the essential qualities of the clinician is interest in humanity, for the secret of the care of the patient is in caring for the patient." 1 Francis Peabody's memorable quote from almost one hundred years ago still rings true today. However, when under pressure in our current medical practices (for example, during the covid-19 pandemic), it can be easy to forget that our human-to-human connections make a difference for our patients. In this article we explore how doctors can consciously use their interest in humanity and the power of caring in their clinical work. We focus on the individual clinician's choices and actions, although we recognise that systematic problems such as limited time with patients also affect the extent to which caring can be brought into a consultation. We define "caring" as a mindset of healthcare professionals that helps them protect the humanity of themselves and others and fosters positive transpersonal relationships that feature love and kindness.2Box 1 exemplifies a consultation in which humanity was shared and that resulted in a major life change for the patient. Box 1 ### A person with neck pain After having every treatment known to man, I was told at the pain management clinic that there was no cure, and that I would never work again as a musician or in fact any other job, because of the pain and its restrictions. They said I would have the pain for life and that it would get worse as I got older. It seemed that, … RETURN TO TEXT
Abstract IA01: Single cell analysis of CRISPR T cells
Authors: Edward Stadtmauer, Joseph Fraietta, Ansuman Satpathy, Carl H. June
Journal: Cancer Research (2020)

Abstract CRISPR-Cas9 gene editing provides a powerful tool to enhance the natural ability of human T cells to fight cancer. We report a first-in-human phase 1 clinical trial to test the safety and feasibility of multiplex CRISPR-Cas9 editing to engineer T cells in three patients with refractory cancer. Two genes encoding the endogenous T cell receptor (TCR) chains, TCRα (TRAC) and TCRβ (TRBC), were deleted in T cells to reduce TCR mispairing and to enhance the expression of a synthetic, cancer-specific TCR transgene (NY-ESO-1). Removal of a third gene encoding programmed cell death protein 1 (PD-1; PDCD1), was performed to improve antitumor immunity. Adoptive transfer of engineered T cells into patients resulted in durable engraftment with edits at all three genomic loci. Although chromosomal translocations were detected, the frequency decreased over time. Modified T cells persisted for up to 9 months, suggesting that immunogenicity is minimal under these conditions and demonstrating the feasibility of CRISPR gene editing for cancer immunotherapy. Citation Format: Edward Stadtmauer, Joseph Fraietta, Ansuman Satpathy, Carl H. June. Single cell analysis of CRISPR T cells [abstract]. In: Proceedings of the AACR Virtual Special Conference on Tumor Heterogeneity: From Single Cells to Clinical Impact; 2020 Sep 17-18. Philadelphia (PA): AACR; Cancer Res 2020;80(21 Suppl):Abstract nr IA01.
Symptoms, Health-Related Quality of Life, and Tolerability of Loncastuximab Tesirine in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma
Authors: Alexander I. Spira, Lei Chen, Xiaolei Zhou, Ari Gnanasakthy, Luqiang Wang, David Ungar, Rafael Curiel, John A. Radford, Brad S. Kahl
Journal: Blood (2020)
To Explore the Effect of Haploidentical Transplantation in the Treatment of Pediatric T-ALL with Sil-TAL1 Fusion Gene Positive and Analysis of Prognostic Factors
Authors: Huili Zhu, Peihua Lu, Deyan Liu, Yanli Zhao, Jiarui Zhou, Jianping Zhang, Xingyu Cao, Yue Lu, Zhijie Wei
Journal: Blood (2020)
<i>Lactobacillus lactis</i> CKDB001 ameliorate progression of nonalcoholic fatty liver disease through of gut microbiome: addendum
Authors: Na Young Lee, Hyun Chae Joung, Byoung Kook Kim, Byung Yong Kim, Tae Sik Park, Ki Tae Suk
Journal: Gut Microbes (2020)

According to our recent study (N.Y. LEE et al. Gut Microbes 2020; 11:882–99.)1, we reported that Lactobacillus and Pediococcus ameliorate progression of nonalcoholic fatty liver disease through modulation of the gut microbiome. According on the analysis method (Previous: 16s rRNA sequencing and Recent: whole gene sequencing), the probiotics named Lactobacillus bulgaricus that we used in the experiment was identified as Lactobacillus delbrueckii subsp. bulgaricus through 16s rRNA sequencing analysis. Recently, we performed a clearer analysis with whole gene sequencing to proceed with the clinical trial, it was identified as Lactobacillus delbrueckii subsp. lactis by whole gene sequencing. Therefore, we inform that the subspecies have been changed to lactis through WGS. Read L. bulgaricus in the previous paper as L. lactis. In this addendum, the results of the change to L. lactis are summarized, and descriptions have been added to Materials & methods and Discussion.
PTPN11 mutations are associated with poor outcomes across myeloid malignancies
Authors: David M. Swoboda, Najla Al Ali, Onyee Chan, Eric Padron, Andrew T. Kuykendall, Jinming Song, Mohammad Hussaini, Chetasi Talati, Kendra Sweet, Jeffrey E. Lancet, David A. Sallman, Rami S. Komrokji
Journal: Leukemia (2020)
Prevalence of Low Limb Venous Thromboembolic Events in Mild and Severe/Critically Ill Patients with COVID-19 Despite Pharmacological Thromboprophylaxis
Authors: Cong Zhang, Jialan Shi, Changjun WU, Chunxu Wang, Xinyi Zhao, Jinming Zhang, Shuoqi Zhang, Yinzhu CHU, Haijiao Jing, Xiaojing Chen, Huan Liu, Jingwen Du, Yufeng Wang, Xiaoming Wu, Yiming Feng
Journal: Blood (2020)
Chemotherapeutic efficacy of curcumin and resveratrol against cancer: Chemoprevention, chemoprotection, drug synergism and clinical pharmacokinetics
Authors: Srimanta Patra, Biswajita Pradhan, Rabindra Nayak, Chhandashree Behera, Laxmidhar Rout, Mrutyunjay Jena, Thomas Efferth, Sujit Kumar Bhutia
Journal: Seminars in Cancer Biology (2020)
Outcomes and Prognostic Scoring System for Elderly Patients with Acute Myeloid Leukemia
Authors: Fumi Nakamura, Sachiko Seo, Honoka Arai, Yuka Nakamura, Tomoyuki Handa, Wataru Takahashi, Shiho Furuichi, Fusako Nagasawa, Jiro Tadokoro, Shigeharu Tsurumi, Yuko Nakamura, Ko Sasaki, Motoshi Ichikawa, Kinuko Mitani
Journal: Blood (2020)
Both the Subtypes of Kit Mutation and Minimal Residual Disease Are Associated with Prognosis in Core Banding Factor Acute Myeloid Leukemia
Authors: Wenbing Duan, Xiaohong Liu, Jinsong JIA, Jing Wang, Lizhong Gong, Qian Jiang, Ting Zhao, Yu Wang, Xiaohui Zhang, Lanping Xu, Xiaosu Zhao, Yazhen Qin, Hongxia Shi, Yingjun Chang, Xiaojun Huang, Hao Jiang
Journal: Blood (2020)
Abstract 483: Novel Evaluation Method of Spheroid
Authors: Hiroshi Matsushita, Shanxiu Xu, Yusheng He, Takahiro Inoue, Vivian Nguyen, Katherine Nurminsky, Narutoshi Hibino
Journal: Circulation Research (2020)

Introduction: The 3D culture methods are growing in importance in various fields, such as tissue engineering, cancer research and drug estimation. There are many methods to create 3D cell aggregation, as known as spheroids, e.g. hanging drop method, low attach U-shape plate, microwell low attach plate, spinning flask and magnetic levitation. In either field, researchers require not only high-scale but also high-quality spheroids creation. However, the method for evaluation of spheroids has not yet established. We established an accurate method of quantification of spheroids by measuring cell density and area of them with NIH Image J. Method: Spheroids were created with a hanging drop method (HD) and 96 well low attach U-shape plate (LAP) by using H9C2 cells, NIH 3T3 cells, human cardiac fibroblast and human dermal fibroblast cells using 22000 cells, 33000 cells and 44000 cells per spheroids. Spheroids were created five times using one of these systems.These spheroids were taken pictures in 10 times magnification with a microscope under constant condition using one tenth of spheroids solution created with HD and LAP and then quantified mean gray value and area using NIH image J. We saw relationship between its cell diameter and these data and also measured the cost and time for creating one spheroid and compared them among these methods. We also compared these data with histological analysis. Result: Spheroids created with HD had no relation between cell number and spheroid quality, whereas those with LAP demonstrated that higher cell numbers created larger and higher density of spheroid consistently. The number of spheroids created with the hanging drop method was higher but more inconstant and the success rate was low. However, Spheroids creation with this method took much less cost and time compared with LAP. We could see a positive correlation between area and cell size and negative correlation between gray value and its cell diameter when we create spheroids with HD with the same kinds of cells, i.e. NIH 3T3 cells, human cardiac fibroblast, and human dermal fibroblast cells. Conclusion: Although HD has the potentiality to create a large number of spheroids at once and this method was cost and time effective, the quality of spheroids was not consistent compared to LAP. The cell diameter influenced the quality of spheroids when we created them with HD.
Excellent Outcomes Achieved with Medical Management of Chronic Phase CML Patients with Non-Hematologic TKI Intolerance
Authors: Kelly L. Schoenbeck, Sirisha Tummala, Rebecca L. Olin, Neha G. Goyal, Anand Dhruva, Lloyd E. Damon, Aaron C. Logan, Catherine C. Smith, Neil P. Shah
Journal: Blood (2020)
Hepatopulmonary Syndrome Mimics Pulmonary Embolism on Pulmonary Ventilation/Perfusion SPECT/CT Study
Authors: Shuxin Zhang, Wei Wang, Xu Yang, Jie Liu, Ji-Gang Yang
Journal: Clinical Nuclear Medicine (2019)

A 64-year-old woman with a history of cirrhosis and progressive difficulty breathing underwent pulmonary ventilation/perfusion SPECT to evaluate possible pulmonary embolism. The images demonstrated multiple mismatched ventilation/perfusion defects in both lungs, suggesting pulmonary embolism. However, there was also Tc-MAA radioactivity in the brain and bilateral kidney, with a right-to-left shunting rate of 8.8%. In addition, CT pulmonary angiography did not demonstrate embolus. The findings indicated that perfusion defects were caused by hepatopulmonary syndrome.
Adjuvant Osimertinib in<i>EGFR</i>-Mutated Non–Small-Cell Lung Cancer
Authors: David Planchard
Journal: New England Journal of Medicine (2020)

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have completely reinvented therapeutic care for patients with metastatic non–small-cell lung cancer (NSCLC) harboring an activating EGFR mutation (Ex19del or L858R). The survival benefit with the third-generation EGFR-TKI osimertinib as compared with the first-generation agents gefitinib and erlotinib1 has cemented its role in the current therapeutic landscape in patients with metastatic disease. However, no such advances have been seen over the past two decades for localized resectable disease. After complete resection, a small but significant survival benefit (5% at 5 years, corresponding to an 11% reduction in the risk of death) . . .
Right Ventricular Strain Curve Morphology and Outcome in Idiopathic Pulmonary Arterial Hypertension
Authors: Roberto Badagliacca, Beatrice Pezzuto, Silvia Papa, Roberto Poscia, Giovanna Manzi, Antonella Pascaretta, Cristiano Miotti, Federico Luongo, Gianmarco Scoccia, Francesco Ciciarello, Gavino Casu, Susanna Sciomer, Francesco Fedele, Robert Naeije, Carmine Dario Vizza
Journal: JACC. Cardiovascular imaging (2020)
Abstract 255: Cardiac Ischemia and Reperfusion Injury: The Emerging Role of Sialidase Neu3
Authors: Marco Piccoli, Maria Elena Canali, Paola Rota, Paolo La Rocca, Andrea Ghiroldi, Federica Cirillo, Luigi Anastasia
Journal: Circulation Research (2020)

Reperfusion strategies, together with thrombolytic therapies, represent life-saving approaches to restore the blood flow in the cardiac tissue after acute myocardial infarction (AMI). However, they inevitably induce the so-called ischemia/reperfusion injury (IRI), resulting in increased cardiomyocytes damage and heart failure. In this context, many efforts have been made to clarify the molecular mechanisms involved in IRI, and the activation of pro-survival kinases, such as Akt and Erk, as well as of the hypoxia-inducible factor (HIF) has been recognized to be critical. Along this line, we discovered a novel mechanism of HIF-1α activation mediated by sialidase Neu3, which is PHDs independent, and that it increased muscle cells resistance to hypoxic stress, through the activation of Akt and Erk pathways. Moreover, an upregulation of Neu3 expression was observed under chronic hypoxia in cyanotic congenital cardiac patients.On these premises, this study aims at investigating the role of Neu3 in protecting cardiac cells against IRI. In particular, H9C2 rat cardiomyoblasts were exposed to an IRI model in vitro revealing a marked reduction in cell proliferation. This was accompanied by the modulation of Neu3 that was characterized by its progressive down-regulation during the ischemic phase, followed by its reactivation during reperfusion. These experiments resembled Neu3 modulation we observed in an IRI mouse model, obtained by the temporary occlusion of the LAD coronary vessel. Interestingly, overexpression of Neu3 significantly increased cardiomyoblasts resistance to IRI, both in terms of cell proliferation and resistance to apoptosis, as well as promoted HIF-1α and Akt/Erk activation. Remarkably, the treatment with Akt and Erk inhibitors completely reverted the beneficial effects mediated by Neu3 upregulation. Likewise, sialidase Neu3 inhibition reduced Akt/Erk activation, resulting in the complete loss of Neu3-mediated cardioprotection. In conclusion, our results demonstrate the role of sialidase Neu3 in counteracting the detrimental effects of IRI, calling for further studies to unveil its full potential as a therapeutic target to support current strategies to manage cardiac damage and to improve patients recover after AMI.
Proposal of a Novel Latin American International Prognostic Index (LATAM-IPI) for Diffuse Large B-Cell Lymphoma (DLBCL) By the Grupo Para El Estudio De Linfoproliferativos En Latino-America (GELL)
Authors: Luis Villela Villela, Ana Ramirez-Ibarguen, Brady E Beltran, Camila Peña, Denisse A. Castro, Gladys P Agreda-Vasquez, Myrna Candelaria, Maria Alejandra Torres Viera, Henry Idrobo, Lorena Fiad, Fabiola Valvert, Efreen Montaño Figueroa, Juan Ospina Idarraga, Alana Von Glasenapp, Sally Paredes, Melani Otañez, Fernando Perez-Jacobo, Daniela Zambrano, Humberto Martínez Cordero, Virginia Otero, Lidiane Andino, Mercedes Royg Arriola, Maria Elvira Enciso, Maria Prates, Cristaldo Nancy, Ivan Perdomo, Maria E Cabrera, María Lorena Cardozo, Cristobal Augusto Frutos Ortiz, Eloisa Riva, Juan Antonio Choque, Alfredo Reinaldo Quiroz, Guilherme Fleury Perini, David Gomez-Almaguer, Guillermo J. Ruiz-Arguelles, Marcos Distefano, Katerine Garcia, Carolina Feres, Mariana Kalmus, Julian Cordova, Magali DelosRios, Rosio Baena, Luis Malpica Castillo, Eduardo Sotomayor, Jorge J. Castillo
Journal: Blood (2020)
N-Linked Glycans on Therapeutic Factor VIII (FVIII) Proteins Attenuate Immunogenicity Potential: Evidence from Independent HLA-Class-II/FVIII (HLAcII/FVIII) Peptidomes
Authors: Vincent P. Diego, Bernadette W. Luu, Hari Movva, Marco Hofmann, Marcio A. Almeida, Long V. Dinh, Jerry S. Powell, Raja Rajalingam, Juan M Peralta, Henry Mead, Satish Kumar, Joanne E. Curran, Miguel A. Escobar, Sarah Williams-Blangero, Eugene Maraskovsky, John Blangero, Tom E. Howard
Journal: Blood (2020)
Checkpoint therapeutic target database (CKTTD): the first comprehensive database for checkpoint targets and their modulators in cancer immunotherapy
Authors: Yixiao Zhang, Yuan Yao, Peng Chen, Yu Liu, Hao Zhang, He Liu, Yu Liu­, Hong Xu, Xibao Tian, Zichu Wang, Peng Chu, Dongyu Zhao, Hongxu Liu, Chenlei Zhang, Shuyuan Chen, Yuhong Zhao, Caigang Liu, Yongliang Yang
Journal: Journal for ImmunoTherapy of Cancer (2020)

Background Checkpoint targets play a key role in tumor-mediated immune escape and therefore are critical for cancer immunotherapy. Unfortunately, there is a lack of bioinformatics resource that compile all the checkpoint targets for translational research and drug discovery in immuno-oncology. Methods To this end, we developed checkpoint therapeutic target database (CKTTD), the first comprehensive database for immune checkpoint targets (proteins, miRNAs and LncRNAs) and their modulators. A scoring system was adopted to filter more relevant targets with high confidence. In addition, a few biological databases such as Oncomine, Drugbank, miRBase and Lnc2Cancer database were integrated into CKTTD to provide an in-depth information. Moreover, we computed and provided ligand-binding site information for all the targets which may support bench scientists for drug discovery efforts. Results In total, CKTTD compiles 105 checkpoint protein targets, 53 modulators (small-molecules and antibody), 30 miRNAs and 18 LncRNAs in cancer immunotherapy with validated experimental evidences curated from 10 649 literatures via an enhanced text-mining system. Conclusions In conclusion, the CKTTD may serve as a useful platform for the research of cancer immunotherapy and drug discovery. The CKTTD database is freely available to public at http://www.ckttdb.org/ .
High-Resolution Binding Atlas of U2AF1 Mutants Uncovers New Complexity in Splicing Alterations and Kinetics in Myeloid Malignancies
Authors: Giulia Biancon, Poorval Joshi, Torben Hunck, Josh Zimmer, Yimeng Gao, Martin Machyna, Valentina Botti, Ashley Qin, Gabriella Viero, Nils Neuenkirchen, Ashley Taylor, Rana Gbyli, Amisha Patel, Anastasia Ardasheva, Xiaoying Fu, Haifan Lin, Matthew D Simon, Karla M Neugebauer, Toma Tebaldi, Stephanie Halene
Journal: Blood (2020)
COVID-19 Outbreak Among a University’s Men’s and Women’s Soccer Teams — Chicago, Illinois, July–August 2020
Authors: Richard A. Teran, Isaac Ghinai, Stephanie Gretsch, Tracy Cable, Stephanie R. Black, Stefan J. Green, Omar Perez, George E. Chlipala, Mark Maienschein-Cline, Kevin J. Kunstman, Susan C. Bleasdale, Marielle J. Fricchione
Journal: MMWR Morbidity and Mortality Weekly Report (2020)

Data on transmission of SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), among college athletes are limited. In August 2020, the Chicago Department of Public Health (CDPH) was notified of a cluster of COVID-19 cases among a university's men's and women's soccer teams. CDPH initiated an investigation, interviewed members of both teams, and collated laboratory data to understand transmission of SARS-CoV-2 within the teams. Numerous social gatherings with limited mask use or social distancing preceded the outbreak. Transmission resulted in 17 laboratory-confirmed COVID-19 cases across both teams (n = 45), likely from a single source introduction of SARS-CoV-2 (based on whole genome sequencing) and subsequent transmission during multiple gatherings. Colleges and universities are at risk for COVID-19 outbreaks because of shared housing and social gatherings where recommended prevention guidance is not followed. Improved strategies to promote mask use and social distancing among college-aged adults need to be implemented, as well as periodic repeat testing to identify asymptomatic infections and prevent outbreaks among groups at increased risk for infection because of frequent exposure to close contacts in congregate settings on and off campus.
The Role of Plasmin/Plasminogen in Experimental Polymicrobial Sepsis
Authors: Juliana Vago, Larissa Froede Brito, Lívia C.R. Teixeira, Izabela Z. Moreira, Thaís C. Miranda, Eliza M. Melo, Alexandre S. Bruno, Michelle A. Sugimoto, Raphael G. Ferreira, Jose C. Alves-Filho, Mauro M. Teixeira, Robert J Parmer, Lindsey A Miles, Lirlandia P. Sousa
Journal: Blood (2020)
Investigating Gut Microbial Taxa and Asparaginase Related Genes in Children Showing Different Direction of Change in Serum Asparaginase Activity Levels during Pegasparaginase Treatment for Acute Lymphoblastic Leukemia
Authors: Ketan Kulkarni, Katherine A Dunn, Jessica Connors, Joseph Bielawski, Jacob Nearing, Morgan Langille, Johan VanLimbergen, Tamara MacDonald
Journal: Blood (2020)
Bosutinib (BOS) Versus Imatinib for Newly Diagnosed Chronic Phase (CP) Chronic Myeloid Leukemia (CML): Final 5-Year Results from the Bfore Trial
Authors: Tim H Brümmendorf, Jorge E. Cortes, Dragana Milojkovic, Carlo Gambacorti-Passerini, Richard E. Clark, Philipp D le Coutre, Valentín Garcia-Gutiérrez, Charles Chuah, Vamsi Kota, Jeffrey H. Lipton, Philippe Rousselot, Michael J. Mauro, Andreas Hochhaus, Rafael Hurtado Monroy, Eric Leip, Simon Purcell, Anne Yver, Andrea Viqueira, Michael W. Deininger
Journal: Blood (2020)
Blast MRD AML-2: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease (MDR) in Acute Myeloid Leukemia (AML) 2- a Randomized Phase 2 Study of the Venetoclax, Azacitidine, and Pembrolizumab Versus Venetoclax and Azacitidine As First Line Therapy in Older Patients with AML Who Are Ineligible or Who Refuse Intensive Chemotherapy
Authors: Amer M. Zeidan, Prajwal Boddu, Brent L Wood, Daniel Zelterman, Richard F. Little, S. Percy Ivy, Anne Caldwell, Beatriz Sanchez-Espiridion, Gheath Alatrash, Elad Sharon, Jerald P. Radich
Journal: Blood (2020)